Geron Corporation (GERN)
GERNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$0.9683
-0.0267 (-2.68%) today
At the close, Nov 10, 4:00 PM ET. After hours $0.9742 –
- Market cap
- $627.62m
- P/E
- –
- EPS, last 4 quarters
- $-0.0600
- Dividend yield
- –
- Day range
- $0.9400 to $1.02
- 52-week range
- $0.8400 to $2.01
- Average volume
- 13.10m
- Previous close
- $0.9950
Analysts
4 coveringHold3 buy, 1 hold, 0 sell
Targets a year out average $3.83, +295.5% from here
Earnings
next estimate $0.00000000Next report
Dec 2025
0.0%
Mar 2026
+66.7%
Jun 2026
-100.0%
Sep 2026
+100.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $48.02m | $51.84m | $57.48m | $60.19m |
| Gross profit | $46.71m | $50.15m | $48.24m | $54.14m |
| Operating income | -$25.54m | $158.0k | -$12.50m | $5.80m |
| Net income | -$28.86m | -$3.64m | -$16.68m | $1.35m |
Last four quarters: revenue $217.52m, margin -22.0%, free cash flow –
News
8 latest- Geron: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 5 days ago
- Geron Corp (GERN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Geron Corporation Reports Third Quarter 2026 Financial Results and Discontinues Phase 3 IMpactMF TrialFintel · 6 days ago
- Geron Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Geron (GERN) Reports Break-Even Earnings for Q3Zacks · 6 days ago
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals RTTNews · Oct 30, 2026
- Geron Corporation Discontinues Phase 3 IMpactMF Trial of Imetelstat in Relapsed/Refractory MyelofibrosisFintel · Oct 29, 2026
- Geron Discontinues Phase 3 IMpactMF Trial Of Imetelstat In Myelofibrosis; Data Analysis Planned RTTNews · Oct 28, 2026
The company
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- geron.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.